Elicio Therapeutics, Inc.
ELTX Nasdaq
SEC CIK 1601485
Follow Elicio Therapeutics
Weekly email: filings, results
Net income
−$8M
+20.9% vs same quarter last year
EPS, diluted
−$0.30
+50% vs same quarter last year
Operating cash flow
−$10.4M
+6.5% vs same quarter last year
Operating income
−$8.5M
−5.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$39.6M |
| FY24 | - | −$51.9M |
| FY23 | - | −$35.2M |
| FY22 | $2.3M | −$28.2M |
| FY21 | $28.3M | −$54.6M |
| FY20 | $2.9M | −$80.1M |
| FY19 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | - | - |
| FY24 | - | - | - |
| FY23 | - | - | - |
| FY22 | 100% | −1031.4% | −1225.9% |
| FY21 | 98.5% | −138.8% | −192.8% |
| FY20 | 58.7% | −1919.2% | −2781.5% |
| FY19 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$37M |
| FY24 | −$37.2M |
| FY23 | −$32.8M |
| FY22 | −$22.8M |
| FY21 | −$53M |
| FY20 | −$22.9M |
| FY19 | - |
- Elicio Therapeutics
- Healthcare median
Show the numbers
| Year | Elicio Therapeutics | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | −1225.9% | −80.4% |
| FY21 | −192.8% | −71.8% |
| FY20 | −2781.5% | −62.2% |
| FY19 | - | −46.2% |